USA flag logo/image

An Official Website of the United States Government

Automated Sample Preparation for Next Generation Sequencing Cancer Diagnostics

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2013 / SBIR
Agency Tracking Number:
R43CA165372
Solicitation Year:
2013
Solicitation Topic Code:
NCI
Solicitation Number:
PA12-088
Small Business Information
ADVANCED LIQUID LOGIC
615 Davis Dr., Suite 800 PO Box 14025 RESEARCH TRIANGLE PARK, NC -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2013
Title: Automated Sample Preparation for Next Generation Sequencing Cancer Diagnostics
Agency: HHS
Contract: 1R43CA165372-01A1
Award Amount: $240,201.00
 

Abstract:

DESCRIPTION (provided by applicant): As more diverse genetic links are established with cancer, the utility of one-gene-one-test diagnostics is diminished. In addition, biopsies are mixed populations of tumor and normal tissue, requiring deconvolution oftumor and non-tumor genoptypes to accurately understand disease etiology and inform treatment decisions. The next generation of cancer diagnostics must therefore achieve two goals: 1) identify genetic variation in a high number of cancer-associated genes and 2) do so in a sample containing a mixed cellular population. Deep sequencing, using the so-called next generation sequencing (NGS) platforms represents a powerful and unique approach to address these challenges. Various capture methods exist, to isolatespecific regions of the genome for sequencing on NGS platforms. Tumor and nontumor genotypes can then be discerned through bioinformatic analysis of the resulting sequencing data. To better enable deep sequencing of tumor biopsies, Advanced Liquid Logic (ALL) will apply its proprietary digital microfluidic liquid handling technology to automate the diagnostic cancer panel assay developed by Foundation Medicine. The resulting prototype system will automate the complex upstream sample preparation system required for NGS analysis of DNA extracted from crude tumor biopsies. ALL will develop a digital microfluidic cartridge capable of DNA purification/concentration, library preparation and targeted enrichment of the cancer-associated genes included in Foundation's panel. By processing these samples in sub-microliter volumes, the ALL platform will also enable analysis of very small biopsy samples, reducing DNA input requirements by 100-1000 fold. In addition to the reliability and labor savings associated with automation, ALL's platform offers cost-effectiveness for non- PCR based sequence capture methods ahead of NGS. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: As high throughput DNA sequencing is beginning to move into clinical applications, thearduous sample preparation that is required is likely to become a significant bottleneck. A microfluidic system which automates these processes within an inexpensive cartridge will be developed.

Principal Investigator:

Nicholas Trotta
919-287-9010
grants@liquid-logic.com

Business Contact:

Deborah Wallace
919-287-9010
grants@liquid-logic.com
Small Business Information at Submission:

ADVANCED LIQUID LOGIC
615 Davis Dr., Suite 800 PO Box 14025 RESEARCH TRIANGLE PARK, NC -

EIN/Tax ID: 120170896
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No